Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2011 (2011), Article ID 356370, 3 pages
http://dx.doi.org/10.1155/2011/356370
Case Report

Vancomycin-Associated Leukocytoclastic Vasculitis

1Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA
2Pharmacy Practice Division, Department of Pharmacy and St. Louis College of Pharmacy, Barnes-Jewish Hospital, MO 63110, USA
3Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA

Received 2 May 2011; Accepted 21 May 2011

Academic Editors: W. I. van der Meijden and S. Yazar

Copyright © 2011 Makhawadee Pongruangporn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Vancomycin is U.S. Food and Drug Administration (FDA) approved for treatment of serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or in individuals who have failed, cannot tolerate, or are allergic to other antibiotics. Very few cases of vancomycin-associated leukocytoclastic vasculitis have been published. We report on a patient who developed pruritus and palpable purpura in both lower extremities after receiving six days of intravenous vancomycin. Skin biopsy revealed leukocytoclastic vasculitis.